# Juri Biosciences

Source: https://onco.cc/companies/juri-biosciences/  
OnCo record `juri-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Juri Biosciences develops JUR-003, an antibody that directs the immune system's T cells to prostate cancer cells carrying a protein called KLK2. It is being tested for the first time in people with metastatic prostate cancer.

## Summary

Juri Biosciences, Inc. is a single-asset portfolio company formed by TCG Labs Soleil, the venture-biotech organisation run in collaboration with The Column Group. In May 2025 Juri took an exclusive worldwide licence from EpimAb Biotherapeutics to a KLK2 x CD3 T-cell engager for metastatic prostate cancer, with EpimAb eligible for up to $210 million in upfront and milestone payments plus royalties. JUR-003, the lead of Juri's KLK2-directed T-cell engagers, is a bispecific antibody designed for subcutaneous dosing. Its first registered cancer trial, NCT07824349, a phase 1a/1b dose-escalation and expansion study of intravenous JUR-003 in metastatic castration-resistant, hormone-sensitive and oligometastatic prostate cancer, was posted on ClinicalTrials.gov in September 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: San Francisco, CA
- Type: biotech

## Notes

- Juri has no website of its own that could be found; facts come from TCG Labs Soleil press releases dated 27 May 2025 and 28 October 2026 and from the registry record, read on 29 October 2026.
- Headquarters city is taken from the San Francisco dateline of the TCG Labs Soleil releases; Juri's own address is not published.
- The October 2026 release describes JUR-003 as designed for subcutaneous administration, while the registry record says it will be given intravenously in this trial.
- Founding year and financing amounts for Juri itself are not stated.

## Sources

- TCG Labs Soleil: Juri and EpimAb KLK2 licence, May 2025: https://www.tcglsoleil.com/news/juri-biosciences-a-tcg-labs-soleil-portfolio-company-and-epimab-biotherapeutics-enter-into-a-worldwide-licensing-agreement-for-klk2-directed-t-cell-engager-in-metastatic-prostate-cancer/
- TCG Labs Soleil: three programmes enter first-in-human trials, October 2026: https://www.tcglsoleil.com/news/tcg-labs-soleil-highlights-portfolio-momentum-with-three-programs-entering-first-in-human-clinical-trials-across-oncology-and-cardiovascular-disease/
- ClinicalTrials.gov: phase 1a/1b trial of JUR-003 in metastatic prostate cancer (NCT07824349): https://clinicaltrials.gov/study/NCT07824349

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Metastatic hormone-sensitive prostate cancer](https://onco.cc/cancers/prostate-mhspc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/), [KLK2 (kallikrein-2)](https://onco.cc/targets/klk2/)

---
JSON: https://onco.cc/api/v1/entities/juri-biosciences.json